[Market Focus] Cellumed Hits Lower Limit on News of L&C Bio Acquisition Cancellation
Cellumed hit the lower price limit in early trading on December 30, following the fallout from the cancellation of the acquisition plan by L&C Bio Group.
As of 9:40 a.m. on this day, Cellumed shares were trading at 1,154 won on the KOSDAQ market, down 29.98% from the previous trading day. The stock opened at 1,203 won and immediately dropped to the lower limit.
The previous day, Cellumed announced that it would change the recipient of its third-party paid-in capital increase from L&C Bio to TD Landmark Fund No. 1. Previously, L&C ES, a subsidiary of L&C Bio, was scheduled to participate in Cellumed's third-party paid-in capital increase, but this plan was canceled. Instead, TD Landmark Fund No. 1 will exclusively receive the allocation of 28,192,370 new shares (with a subscription amount of 17 billion won) in their place.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
The payment date for the paid-in capital increase has been changed from December 30 to January 22 of the following year. After the capital increase, TD Landmark Fund No. 1 will become the new largest shareholder of Cellumed, replacing the current largest shareholder, Insko B.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.